Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.50 |
| ▸ | JAK1 | P23458 | 19/20 | 0.50 |
| ▸ | TYK2 | P29597 | 19/20 | 0.50 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16424402 | 0.99 | JAK2 (0.49) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16606000 | 0.94 | TYK2 (0.50) | JAK2JAK1TYK2JAK3KDR | |
| Hydrochloric Acid SCHEMBL16423252 | 0.93 | TYK2 (0.49) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16423412 | 0.83 | JAK2 (0.53) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16606011 | 0.82 | JAK2 (0.52) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16606006 | 0.82 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KDR | |
| Hydrochloric Acid SCHEMBL16424182 | 0.81 | JAK2 (0.51) | JAK2JAK1TYK2JAK3KDR | |
| Hydrochloric Acid SCHEMBL16423487 | 0.81 | JAK2 (0.48) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16423134 | 0.78 | JAK2 (0.51) | JAK2JAK1TYK2JAK3KDR | |
| SCHEMBL16423514 | 0.78 | JAK1 (0.47) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | JAK2 14/4885JAK1 15/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.